Do Traders Think Dare Bioscience Inc (DARE) Can Turn Around Thursday?

Dare Bioscience Inc (DARE) stock is lower by 5.34% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Dare Bioscience Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on DARE!

See Full DARE Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With DARE Stock Today?

Dare Bioscience Inc (DARE) stock is trading at $1.24 as of 12:37 PM on Thursday, Jun 30, a loss of -$0.01, or -0.76% from the previous closing price of $1.25. Volume today is above average. So far 2,170,944 shares have traded compared to average volume of 1,177,339 shares. The stock has traded between $1.18 and $1.28 so far today.

More About Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Click Here to get the full Stock Report for Dare Bioscience Inc stock.